Study of lung cancer with rare gene changes
Part of Cancer, Lungs & breathing clinical trials.
This trial looks at the “molecular landscape,” meaning the specific gene changes driving your lung cancer, for people whose non-small cell lung cancer (NSCLC) has rare mutations. The goal is to better understand what those rare changes mean and how they could guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with NSCLC (non-small cell lung cancer) that was confirmed by tissue/pathology testing
- Your cancer has a rare gene change, such as one of these: EGFR rare mutations, ALK fusion, ROS1 fusion, BRAF V600E, cMET exon 14 skipping, KRAS G12C, RET fusion, or NTRK fusion
- You are 18 years old or older
- You can understand the study information and are willing to sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial collects tissue samples from your lung tumor and any tumors that have spread to other parts of your body. They will study the genetic makeup of these samples to better understand lung cancer and improve future treatments.
This trial tests REGN5093, a study drug, in adults with advanced lung cancer that has a specific change called a MET alteration. If you have this MET change, the study aims to see how well the drug controls the cancer and how safe it is.
This trial tests a treatment for people with advanced non-small cell lung cancer that has spread to the brain or spine. It is for those whose cancer has a specific EGFR mutation (19Del or L858R) and who have not yet received treatment for their advanced cancer.
This study looks at the genetic changes in ALK-positive lung cancer over time. It is for people who have already started one of three targeted treatments (alectinib, brigatinib, or lorlatinib) and are willing to provide extra tissue or blood samples for testing.
This trial studies how well targeted therapy works for advanced non-small cell lung cancer (NSCLC) that has spread. You may qualify if you have a specific gene change and are starting your first targeted treatment.
This trial looks at the genetic changes in non-small cell lung cancer (NSCLC) that has stopped responding to targeted therapy pills. It aims to understand why the cancer became resistant, which may help find better treatments.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.